Alzamend Neuro, Inc.
ALZN · XNASCIK 1677077fmd_07YJA2TYX16T8AWKNWNRMNMZ3YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: May 01, 2019 to Jul 31, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
| Net interest income | 0 | 0 | – | – | – | – | – |
| Research and development | 1 | 1 | 5 | 7 | 6 | 1 | 4 |
| Total operating expenses | – | – | – | 15 | 10 | 4 | 9 |
| Operating income | (4) | (5) | (12) | (15) | (10) | (4) | (9) |
| Interest expense | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | 0 |
| Other non-operating income (expense) | 0 | (0) | (0) | (0) | (0) | (0) | (0) |
| Income before taxes | (4) | (5) | (12) | (15) | (10) | (5) | (9) |
| Net income | (4) | (5) | (12) | (15) | (10) | (5) | (9) |
| Net income to common shareholders | – | – | – | – | (10) | (5) | (9) |